21 results on '"Heather L. Huelster"'
Search Results
2. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease
- Author
-
Kyle M. Rose, Heather L. Huelster, Joshua J. Meeks, Bishoy M. Faltas, Guru P. Sonpavde, Seth P. Lerner, Jeffrey S. Ross, Philippe E. Spiess, G. Daniel Grass, Rohit K. Jain, Ashish M. Kamat, Aram Vosoughi, Liang Wang, Xuefeng Wang, and Roger Li
- Subjects
Urology - Published
- 2023
3. Contemporary Management of Chylous Ascites after Retroperitoneal Surgery: Development of an Evidence-Based Treatment Algorithm
- Author
-
Kyle M. Rose, Heather L. Huelster, Erica C. Roberts, Brandon J. Manley, Scott M. Gilbert, and Wade J. Sexton
- Subjects
Urology ,Humans ,Lymphography ,Retroperitoneal Space ,Chylous Ascites ,Embolization, Therapeutic ,Algorithms - Abstract
Chylous ascites (CA) is an uncommon complication that occurs from traumatic disruption of lymphatic channels after retroperitoneal surgery. The purpose of this study was to generate an evidence-based management strategy for CA by reviewing the current literature and available treatment modalities.A MEDLINE® literature review was performed for "chylous ascites." Individual patient data were extracted from case series and reports to create an efficacy analysis. Treatment modality, drain output, time to escalation of care and time to resolution were recorded. The efficacy analysis was utilized to generate a data-driven treatment algorithm.The literature review yielded 1,953 articles, from which 146 studies contributed data for 523 patients. The efficacy analysis included 245 patients, 168 (69%) of whom were managed successfully with conservative management (CM), at a median time to resolution of 11 days. Forty-eight patients underwent lymphangiography±embolization after CM, with a success rate of 85%. Thirty-one (12%) patients underwent surgical exploration. When treating CA, the patients who underwent stepwise management with CM followed by lymphangiography if CM failed experienced a resolution rate of 96.7%. An evidence-based treatment algorithm was created to guide treatment selection and duration of therapy before escalating to additional forms of therapy.In this report, we describe the largest conglomeration of iatrogenic CA cases from a literature review (523 cases) and efficacy analysis (245 cases), and created the first evidence-based treatment algorithm for this condition. Treatment success is substantial when using a stepwise combination of CM followed by lymphangiography±embolization.
- Published
- 2022
4. Novel Use of ctDNA to Identify Muscle-Invasive and Non-Organ Confined Upper Tract Urothelial Carcinoma
- Author
-
Heather L Huelster, Billie Gould, Elizabeth A Schiftan, Lucia Camperlengo, Facundo Davaro, Kyle M Rose, Alex C Soupir, Shidong Jia, Tiantian Zheng, Wade J Sexton, Julio Pow-Sang, Philippe E Spiess, G. Daniel Grass, Liang Wang, Xuefeng Wang, Aram Vosoughi, Andrea Necchi, Joshua J Meeks, Bishoy M Faltas, Pan Du, and Roger Li
- Abstract
PURPOSEOptimal patient selection for neoadjuvant chemotherapy prior to surgical extirpation is limited by the inaccuracy of contemporary clinical staging methods in high-risk upper tract urothelial carcinoma (UTUC). We investigated whether the detection of plasma circulating tumor DNA (ctDNA) can predict muscle-invasive and non-organ confined (MI/NOC) UTUC.PATIENTS AND METHODSPlasma cell-free DNA was prospectively collected from chemotherapy-naïve, high-risk UTUC patients undergoing surgical extirpation and sequenced using a 152-gene panel and low-pass whole-genome sequencing. To test for concordance, whole exome sequencing was performed on matching tumor samples. The performance of ctDNA for predicting MI/NOC UTUC was summarized using area under a receiver-operating curve and the optimal variant count threshold determined using Younden’s J statistic. Kaplan-Meier methods estimated survival, and Mantel-Cox log-rank testing assessed the association between preoperative ctDNA positivity and clinical outcomes.RESULTSOf 30 patients prospectively enrolled, 14 were found to have MI/NOC UTUC. At least one ctDNA variant was detected from 21/30 (70%) patients with 52% concordance with matching tumor samples. Detection of at least two panel-based molecular alterations provided the optimal sensitivity and specificity to predict MI/NOC UTUC. Imposing this threshold in combination with a plasma copy number burden score >6.5 achieved a sensitivity of 79% and specificity of 94% in predicting MI/NOC UTUC. Furthermore, the presence of ctDNA was strongly prognostic for progression-free survival (1-yr PFS 69% vs. 100%, pCONCLUSIONThe detection of plasma ctDNA prior to extirpative surgery was highly predictive of MI/NOC UTUC and strongly prognostic of PFS and OS. Preoperative ctDNA demonstrates promise as a biomarker for selecting patients to undergo neoadjuvant chemotherapy prior to nephroureterectomy.
- Published
- 2023
5. Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease
- Author
-
Kyle M. Rose, Heather L. Huelster, Joshua J. Meeks, Bishoy M. Faltas, Guru P. Sonpavde, Seth P. Lerner, Jeffrey S. Ross, Philippe E. Spiess, G. Daniel Grass, Rohit K. Jain, Ashish M. Kamat, Aram Vosoughi, Liang Wang, Xuefeng Wang, and Roger Li
- Subjects
Urology - Published
- 2023
6. Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility
- Author
-
Heather L. Huelster, Logan Zemp, Kea Turner, Brian D. Gonzalez, Heather Jim, L. Robert Gore, and Scott M. Gilbert
- Subjects
Urology - Abstract
Mobile health technology and integration of patient-reported outcome measures into clinical interventions have the potential to transform patient care. Though patient-reported outcome measure management has been shown to improve outcomes in ambulatory care settings, few studies have examined remote patient-reported outcome measure assessment after major cancer surgery.A multiphased feasibility and usability study was designed. A mobile app-based postoperative symptom intervention tool was developed and evaluated by a focus group of bladder cancer patients and caregivers. Patients were prospectively accrued prior to cystectomy and asked to complete the daily mobile postoperative symptom intervention tool and wear biometric monitoring devices for 30 days post discharge. Retention, postoperative symptom intervention tool completion, and usability were assessed. Exploratory analysis of daily symptoms and patient-generated health information correlated signals with postsurgical complications and hospital readmission.Fifteen patients with a median age of 72 years completed 78% of daily surveys over the 30-day recovery period. Average time to complete the postoperative symptom intervention tool was 152 seconds. All patients agreed that the daily survey was easy to use, and most reported it would be a better way to communicate with the care team about symptoms than calling the clinic. Frequency and severity of patient-reported symptoms appeared to cluster prior to or at the time of complication or unplanned health care encounters on visual-analogue mapping.Using smartphone and wearable technology to capture patient-reported symptoms and biometric data is feasible and rated as highly usable by bladder cancer patients after cystectomy. Symptom scores may signal developing complications and help clinicians identify postsurgical patients who may benefit from intervention.
- Published
- 2022
7. Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function
- Author
-
Daniel D. Joyce, Michael Goodman, Antoinette M. Stroup, Xiao-Cheng Wu, Mia Hashibe, Ann S. Hamilton, Amy N. Luckenbaugh, Zhiguo Zhao, Tatsuki Koyama, Christopher J.D. Wallis, Matthew R. Cooperberg, Sherrie H. Kaplan, Li-Ching Huang, Daniel A. Barocas, Karen E. Hoffman, Ralph Conwill, David F. Penson, Brock O' Neil, Lisa E. Paddock, Heather L. Huelster, and Sheldon Greenfield
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Urology ,Population ,030232 urology & nephrology ,Androgen deprivation therapy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,education ,Retrospective Studies ,Libido ,education.field_of_study ,business.industry ,Prostatic Neoplasms ,Androgen Antagonists ,Prostate-Specific Antigen ,medicine.disease ,Erectile dysfunction ,Sexual dysfunction ,030220 oncology & carcinogenesis ,Cohort ,Androgens ,medicine.symptom ,Sexual function ,business - Abstract
Sexual dysfunction, including erectile dysfunction and loss of libido, are common among men undergoing treatment for localized prostate cancer. Both local treatments and systemic androgen deprivation therapy may contribute to these outcomes and are differentially indicated based on disease characteristics. We sought to compare sexual function through 5 years after radiation treatment with and without androgen deprivation therapy in men with good baseline sexual function to better understand long-term effects in this understudied subset of patients. We retrospectively reviewed a prospectively assembled population-based cohort of men who underwent radiation with and without androgen deprivation therapy for intermediate or high-risk localized prostate cancer. Sexual function was assessed longitudinally over 5 years. Men with erections sufficient for intercourse at baseline were selected for inclusion. Out of 167 patients included, 73 underwent radiation alone and 94 received androgen deprivation therapy plus radiation (51 with intermediate and 43 with high-risk disease). Androgen deprivation therapy use was associated with worse sexual function through 1 year regardless of disease risk. This difference was no longer statistically significant at 3 years in the intermediate-risk group. Compared to radiation alone, androgen deprivation therapy in high-risk disease was associated with worse sexual function at 3 years (effect: −20.3 points, CI [−31.8, −8.8], p
- Published
- 2021
8. Neoadjuvant pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer prior to radical cystectomy
- Author
-
Kyle M Rose, Marco Bandini, Heather L Huelster, Giuseppe Basile, Shreyas U Naidu, Philippe E. Spiess, Andrea Necchi, and Roger Li
- Subjects
Cancer Research ,Oncology - Abstract
513 Background: There is an unmet need for systemic treatment options in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy. The PURE-01 trial has also demonstrated preliminary efficacy when pembrolizumab is used in the neoadjuvant setting. We aimed to compare pathologic response and survival outcomes in cisplatin-ineligible patients receiving neoadjuvant pembrolizumab (NAP) vs. immediate radical cystectomy (IRC). Methods: Cisplatin-ineligible MIBC patients were identified from the PURE-01 trial and compared against cisplatin-ineligible MIBC patients treated with immediate radical cystectomy (IRC). Overall survival was analyzed using Kaplan-Meier and Cox Proportional Hazards Modelling. IRC patients were matched via nearest neighbor propensity technique to cisplatin-ineligible patients from PURE-01 by ECOG status, GFR, age, sex, and clinical T stage. Results: Thirty-nine cisplatin-ineligible patients treated with NAP were identified from PURE-01, and compared against 313 cisplatin-ineligible patients undergoing IRC (Figure 1A). OS was prolonged in the NAP patients, with median survival of 19 months in the IRC vs. not reached (NR) in the NAP group (p=
- Published
- 2023
9. Complimentary genomic, pathologic, and artificial intelligence analysis on low-grade noninvasive bladder cancer to predict downstream recurrence
- Author
-
Kyle M. Rose, Aram Vosoughi, Gustavo Borjas, Heather L Huelster, Philippe E. Spiess, Anders E. Berglund, Wade J. Sexton, Anirudh Joshi, Nagi B. Kumar, and Roger Li
- Subjects
Cancer Research ,Oncology - Abstract
553 Background: Low-grade noninvasive (LGTa) bladder cancer is a relatively quiescent but heterogenous malignancy, characterized by downstream recurrences requiring repeated transurethral resections and frequent surveillance. Investigations to elucidate drivers of recurrence have been sparse, but will help risk-stratify patients with LGTa and allow augmentation of follow up protocols. Methods: Patients with LGTa index tumors were stratified by those with no downstream recurrences (nonrecurrent) vs. those with later recurrences (recurrent). RNA sequencing identified differentially expressed genes (DEGs), deconvoluted for cell-type using xCell. Pathologic analysis was performed by a genitourinary pathologist, then a deep-learning artificial intelligence (AI) platform was leveraged to correlate recurrence risk and recurrence-free survival (RFS) based on deep-learning algorithm of segmented nuclei. Results: Thirty index bladder tumors/patients were identified, 18 (60%) of which had later recurrence (Table). There were 238 DEGs recognized, with recurrent tumors expressing signatures for epithelial mesenchymal transition, myogenesis, TNFα signaling via NFκB, and angiogenesis. Recurrent tumors also demonstrated a higher tissue micoenvironment, stroma, and cancer-associated fibroblast score. Pathologic TME analysis validated these findings, with recurrent tumors demonstrating a higher frequency of inverted growth pattern and a higher median stroma percentage. Finally, the AI-derived signature was predictive of recurrence and risk-stratified the cohort (HR= 5.43 [95% CI 1.1-26.76]) for predicting high vs. low risk of recurrence. Patients in the high risk group had a 87.5% recurrence rate while those in the low risk group had a 28.5% recurrence rate (p
- Published
- 2023
10. Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
- Author
-
Amy N. Luckenbaugh, Mary E. Hall, Christopher J.D. Wallis, Kelvin A. Moses, Aaron A. Laviana, Zachary Klaassen, Kirk A. Keegan, and Heather L. Huelster
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Disease ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Randomized controlled trial ,Prostate ,law ,Internal medicine ,Medicine ,Enzalutamide ,Pharmacology (medical) ,business.industry ,Apalutamide ,Abiraterone acetate ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Docetaxel ,030220 oncology & carcinogenesis ,business ,medicine.drug - Abstract
Introduction The treatment landscape for patients with metastatic hormone-sensitive prostate cancer (mHSPC) has changed dramatically in the past five years, despite little change in the preceding 20 years. Such rapid change can make it difficult for clinicians to remain abreast of the current literature and synthesize the relevant data to inform evidence-based treatment decisions. Methodology We performed a narrative, comprehensive review of treatment options for patients with mHSPC as of December 31, 2019. Specifically, we focused on phase II and III randomized controlled trials assessing the role of chemotherapy, novel androgen axis targeting agents, local-(prostate) directed therapy, and metastasis-directed therapy. Results The data support a survival benefit with the addition of four different agents to androgen deprivation among men with newly diagnosed prostate cancer-docetaxel, abiraterone acetate, enzalutamide, and apalutamide. While not directly compared, the efficacy of these agents appears similar. That said, there are differences in their toxicity profiles and notable differences in cost between agents. Although analyses encompassing men with low- and high-volume metastases failed to demonstrate a significant survival benefit for radiotherapy treatment to the prostate, new data demonstrates a benefit for men with low-volume metastatic disease. Ongoing trials will assess whether this applies to local surgical treatment. Similarly, metastasis-directed therapy appears beneficial among carefully selected patients. Conclusion Treatment options for patients with mHSPC are rapidly changing following years of stagnation. A number of systemic therapies offer benefit without significant clinical differences between them. The role for local treatment of the prostate as well as metastatic sites continues to evolve.
- Published
- 2020
11. Editorial Comment
- Author
-
Heather L. Huelster and Kristen R. Scarpato
- Subjects
Urology - Published
- 2021
12. Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma
- Author
-
Heather L Huelster, Elizabeth A. Green, Alex C. Soupir, Kyle M. Rose, Esther N. Katende, Shreyas U Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Alice Yu, Philippe E. Spiess, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, and Roger Li
- Subjects
Cancer Research ,Oncology - Abstract
4587 Background: Upper tract urothelial carcinoma (UTUC) is an aggressive cancer for which use of neoadjuvant chemotherapy (NAC) is limited by suboptimal clinical staging prior to nephroureterectomy. Detection of circulating tumor DNA (ctDNA) is associated with locally advanced and metastatic urothelial carcinoma of the bladder and may help identify UTUC patients who would benefit from NAC. Here we examine the feasibility and utility of plasma ctDNA in the diagnosis of non-organ confined high-risk UTUC. Methods: Patients with high-grade cTa-T2 UTUC without radiographic evidence of metastatic disease undergoing up-front radical nephroureterectomy (RNU) were prospectively accrued for pre- and post-operative plasma collection. Blood was collected preoperatively on the day of surgery, and plasma and buffy coat were processed for extraction of cell-free DNA and genomic DNA, respectively. FFPE tumor samples from RNU were used for tissue genomic DNA extraction. Targeted next-generation sequencing (NGS) was used for variant profiling. ctDNA positivity was defined as the presence of plasma cell-free DNA variants concordant with tissue-based variants. Results: NGS analyses of matched FFPE and plasma samples were successfully performed for all 19 accrued UTUC patients. Alterations in the TERT promoter (74%), TP53 (58%), FGFR3 (53%), myc amplification (53%), and ATM (42%) were demonstrated in urothelial tumor tissue. Matched plasma ctDNA showed prevalent alterations in the TERT promoter (42%), TP53 (42%), PIK3CA (37%), ATM (32%) and CD274 (26%). Nine patients (47%) had detectable plasma ctDNA mutations concordant with tumor-specific variants using the targeted NGS panel. All patients with detectable preoperative ctDNA had advanced staging (≥pT2 or ≥pN1) and lymphovascular invasion on final pathology, resulting in a 90% sensitivity. The panel was 100% specific with no patients with pTis, pTa, pT1 and pN0 having detectable concordant ctDNA mutations. Concordant plasma ctDNA was detected in four of nine patients postoperatively. Two of three (67%) who developed metastatic disease had detectable ctDNA while neither of the two who developed non-muscle-invasive bladder recurrences did. Conclusions: Prospective ctDNA analysis using a targeted NGS panel can be used to predict muscle-invasive and non-organ-confined UTUC preoperatively. Detectable postoperative ctDNA may indicate residual disease and predate clinical recurrence.
- Published
- 2022
13. Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study
- Author
-
Diana Magee, Mohit Butaney, Merry W. Ma, Amy N. Luckenbaugh, Mary E. Hall, Nancy B. Davis, Christopher J.D. Wallis, Martha K. Terris, Aaron A. Laviana, Amanda Hird, Heather L. Huelster, Zachary Klaassen, and Kyle Dymanus
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Medical Oncology ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,Epidemiology ,Medicine ,Humans ,030212 general & internal medicine ,Thyroid cancer ,Drug Approval ,business.industry ,United States Food and Drug Administration ,Incidence (epidemiology) ,Cancer ,medicine.disease ,United States ,Clinical trial ,Observational Studies as Topic ,030220 oncology & carcinogenesis ,Cohort ,Observational study ,Female ,business ,Cohort study - Abstract
BACKGROUND Ensuring representative data accrual in clinical trials is important to safeguard the generalizability of results and to minimize disparities in care. This study's goal was to evaluate differences in gender representation in trials leading to US Food and Drug Administration (FDA) cancer drug approvals. METHODS An observational study was conducted from January 2014 to April 2019 using PubMed and the National Institutes of Health trials registry for primary trial reports. The National Cancer Institute's Surveillance, Epidemiology, and End Results program and US Census were consulted for national cancer incidence. The outcome was an enrollment incidence disparity (EID), which was calculated as the difference between male and female trial enrollment and national incidence, with positive values representing male overrepresentation. RESULTS There were 149 clinical trials with 59,988 participants-60.3% and 39.7% were male and female, respectively-leading to 127 oncology drug approvals. The US incidence rates were 55.4% for men versus 44.6% for women. Gender representation varied by specific tumor type. Most notably, women were underrepresented in thyroid cancer (EID, +27.4%), whereas men were underrepresented in soft tissue cancer (EID, -26.1%). Overall, women were underrepresented when compared with expected incidence (EID, +4.9%; 42% of trials). CONCLUSIONS For many specific tumor types, women are underrepresented in clinical trials leading to FDA oncology drug approvals. It is critical to better align clinical trial cohort demographics and the populations to which these data will be extrapolated. LAY SUMMARY This study assesses whether gender disparities exist in clinical trials leading to US Food and Drug Administration (FDA) cancer drug approvals. From January 2014 to April 2019, 149 clinical trials leading to FDA oncology drug approvals showed 60.3% and 39.7% of the enrollees were male and female, respectively. Gender representation varied by specific tumor when compared with the expected incidence rate of cancer in the United States, although women were more often underrepresented. Increased efforts are needed with regard to ensuring equitable representation in oncology clinical trials.
- Published
- 2021
14. Novel use of ctDNA to identify locally advanced and metastatic upper tract urothelial carcinoma
- Author
-
Heather L. Huelster, Elizabeth A. Green, Alex C. Soupir, Esther N. Katende, Kyle M. Rose, Shreyas U. Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Philippe E. Spiess, Alice Yu, Youngchul Kim, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, and Roger Li
- Subjects
Cancer Research ,Oncology - Abstract
543 Background: Upper tract urothelial carcinoma (UTUC) is an aggressive cancer for which use of neoadjuvant chemotherapy (NAC) is limited by suboptimal clinical staging prior to nephroureterectomy. Detection of circulating tumor DNA (ctDNA) is associated with locally advanced and metastatic urothelial carcinoma of the bladder and may help identify UTUC patients who would benefit from NAC. Here we examine the feasibility and utility of plasma ctDNA in the diagnosis of non-organ confined high-risk UTUC. Methods: Patients with high-grade cTa-T2 UTUC without radiographic evidence of metastatic disease undergoing up-front radical nephroureterectomy (RNU) were prospectively accrued. Blood was collected preoperatively on the day of surgery, and plasma and buffy coat were processed for extraction of ctDNA. FFPE samples from RNU were used for tissue genomic DNA extraction. Next-generation sequencing (NGS) was used for variant profiling. Plasma and somatic tissue mutations were called by comparing with matched buffy coat samples. Detection of cancer variants with a mutation allele frequency (MAF) ≥ 0.25% and hotspot variants with a MAF down to 0.1% were reported for plasma samples targeted by a NGS panel (PredicineCARE). Variants with a MAF ≥ 5% and hotspot variants with a MAF down to 2% were reported for FFPE samples. Results: NGS analyses of matched FFPE and plasma samples were successfully performed for all 15 accrued UTUC patients. Alterations in MYC amplification (62%), TERT promoter (62%), TP53 (38%), FGFR3 (31%), ERBB2 (25%), ARID1A (19%), and PIK3CA (19%) were demonstrated in urothelial tumor tissue. Matched plasma ctDNA showed prevalent alterations in the TERT promoter (47%), TP53 (30%), ARID1A (20%), ERBB2 (20%), FGFR3 (20%), and PIK3CA (17%). Five patients (33%) had detectable plasma ctDNA mutations concordant with tumor-based genotypes using the targeted NGS panel. All patients with detectable preoperative ctDNA had advanced staging (≥pT2 or ≥pN1) and lymphovascular invasion on final pathology, resulting in a 71.4% sensitivity. The panel was 100% specific with no patients with pTis, pTa, or pT1 and pN0 having detectable concordant ctDNA mutations. Conclusions: Prospective ctDNA analysis using a targeted NGS panel is a feasible nonsurgical approach to prediction of high-risk UTUC and has the potential for identification of upper tract urothelial cancer patients that may benefit from NAC.
- Published
- 2022
15. Editorial Commentary
- Author
-
Heather L. Huelster and Kelvin A. Moses
- Subjects
Urology - Published
- 2021
16. Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer
- Author
-
Mark C. Xu, Blair T. Stocks, Svetlana Avulova, Heather L. Huelster, Heidi J. Silver, Jeremy B. Hatcher, Kelvin A. Moses, and Zachary A. Glaser
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Sarcopenia ,Urology ,Radiodensity ,030232 urology & nephrology ,Castrate-resistant prostate cancer ,Article ,03 medical and health sciences ,Prostate cancer ,Low muscle mass ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Humans ,Obesity ,Neoplasm Metastasis ,Muscle, Skeletal ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Survival Rate ,Prostatic Neoplasms, Castration-Resistant ,Adipose Tissue ,Body Composition ,business ,Tomography, X-Ray Computed ,Body mass index - Abstract
PURPOSE: Obesity (body mass index 30 kg/m(2) or greater) is associated with better overall survival in metastatic prostate cancer. Conversely, low muscle mass (sarcopenia) and low muscle radiodensity (myosteatosis) are associated with worse overall survival in many cancers. This study seeks to evaluate the relationship of sarcopenia, myosteatosis and obesity with overall survival in men with metastatic or castrate-resistant prostate cancer. MATERIALS AND METHODS: Retrospective analysis of men with metastatic or castrate-resistant prostate cancer and computerized tomography of abdomen/pelvis presenting to the Vanderbilt Comprehensive Prostate Cancer Clinic from 2012 to 2017 was performed. Demographic, pathological and survival data were described, with sarcopenia and myosteatosis determined from abdominal skeletal muscle area and skeletal muscle radiodensity, respectively. Kaplan-Meier curves and log-rank tests estimated the effect of body composition on survival. Multivariable Cox proportional hazard models were performed adjusting for age, Charlson comorbidity index, race and clinical stage. ANOVA was used to compare obese and nonobese men with and without sarcopenia or myosteatosis. RESULTS: Of 182 men accrued, 37.4% were obese, 53.3% sarcopenic and 59.3% myosteatotic. Over a median followup of 33.9 months, body mass index was associated with reduced mortality (HR 0.93, p=0.02), as was visceral adiposity (HR 0.99, p=0.003). Men with high body mass index without sarcopenia/myosteatosis lived significantly longer than men with high body mass index with sarcopenia/myosteatosis or normal body mass index men (F[3,91]=4.03, p=0.01). CONCLUSIONS: Both high body mass index and visceral adiposity in metastatic or castrate-resistant prostate cancer are associated with reduced mortality, independent of sarcopenia and myosteatosis. Therefore, routine clinical workup should include calculation of body mass index and measurement of waist circumference. Morphometric analysis of computerized tomography imaging can identify patients at risk for poor prognosis.
- Published
- 2020
17. Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes
- Author
-
Heather L. Huelster, Sheldon Greenfield, Xiao-Cheng Wu, Zhiguo Zhao, Ann S. Hamilton, Sherrie H. Kaplan, Li-Ching Huang, Daniel A. Barocas, Karen E. Hoffman, Antoinette M. Stroup, Michael Goodman, Brock O'Neil, Ralph Conwill, David F. Penson, Daniel D. Joyce, Tatsuki Koyama, Aaron A. Laviana, Lisa E. Paddock, Matthew R. Cooperberg, and Mia Hashibe
- Subjects
Urologic Diseases ,Male ,medicine.medical_specialty ,Aging ,Time Factors ,Urology ,Urinary system ,medicine.medical_treatment ,Erectile function ,Oncology and Carcinogenesis ,030232 urology & nephrology ,Outcomes ,Article ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,7.1 Individual care needs ,Prostate ,Clinical Research ,medicine ,Humans ,Patient Reported Outcome Measures ,Postoperative Period ,Prospective Studies ,Cancer ,Aged ,Prostatectomy ,Radiation ,business.industry ,Evaluation of treatments and therapeutic interventions ,Prostatic Neoplasms ,Urology & Nephrology ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Confidence interval ,Radiation therapy ,medicine.anatomical_structure ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Observational study ,Management of diseases and conditions ,Sexual function ,business ,6.4 Surgery - Abstract
Introduction and objectiveThe timing of radiotherapy (RT) after prostatectomy is controversial, and its effect on sexual, urinary, and bowel function is unknown. This study seeks to compare patient-reported functional outcomes after radical prostatectomy (RP) and postprostatectomy radiation as well as elucidate the timing of radiation to allow optimal recovery of function.MethodsThe Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based, observational study of men with localized prostate cancer. Patient-reported sexual, urinary, and bowel functional outcomes were measured using the 26-item Expanded Prostate Index Composite at baseline and at 6, 12, 36, and 60 months after enrollment. Functional outcomes were compared among men undergoing RP alone, post-RP adjuvant radiation (RP + aRT), and post-RP salvage radiation (RP + sRT) using multivariable models controlling for baseline clinical, demographic, and functional characteristics.ResultsAmong 1,482 CEASAR participants initially treated with RP for clinically localized prostate cancer, 11.5% (N = 170) received adjuvant (aRT, N = 57) or salvage (sRT, N = 113) radiation. Men who received post-RP RT had worse scores in all domains (sexual function [-9.0, 95% confidence interval {-14.5, -3.6}, P < 0.001], incontinence [-8.8, {-14.0, -3.6}, P < 0.001], irritative voiding [-5.9, {-9.0, -2.8}, P < 0.001], bowel irritative [-3.5, {-5.8, -1.2}, P = 0.002], and hormonal function [-4.5, {-7.2, -1.7}, P = 0.001]) compared to RP alone at 5 years of follow-up. Compared to men treated with RP alone in an adjusted linear model, sRT was associated with significantly worse scores in all functional domains. aRT was associated with significantly worse incontinence, urinary irritation, and hormonal function domain scores compared to RP alone at 5 years of follow-up. On multivariable modeling, RT administered approximately 24 months after RP was associated with the smallest decline in sexual domain score, with an adjusted mean decrease of 8.85 points (95% confidence interval [-19.8, 2.1]) from post-RP, pre-RT baseline.ConclusionsIn men with localized prostate cancer, post-RP RT was associated with significantly worse sexual, urinary, and bowel function domain scores at 5 years compared to RP alone. Radiation delayed for approximately 24 months after RP may be optimal for preserving erectile function compared to radiation administered closer to the time of RP.
- Published
- 2020
18. MP53-06 RADIOTHERAPY AFTER RADICAL PROSTATECTOMY: EFFECT OF TIMING OF POST-PROSTATECTOMY RADIATION ON FUNCTIONAL OUTCOMES
- Author
-
Heather L. Huelster, Karen E. Hoffman, Ralph Conwill, David F. Penson, Tatsuki Koyama, Zhiguo Zhao, Li-Ching Huang, Daniel A. Barocas, Daniel D. Joyce, and Aaron A. Laviana
- Subjects
Radiation therapy ,medicine.medical_specialty ,Prostatectomy ,business.industry ,Urology ,Urinary system ,medicine.medical_treatment ,medicine ,Bowel function ,business ,Post prostatectomy - Abstract
INTRODUCTION AND OBJECTIVE:The timing of radiation after prostatectomy is controversial, and its effect on patient-reported sexual, urinary, and bowel function is unknown. This study seeks to compa...
- Published
- 2020
19. MP53-04 RECOVERY OF SEXUAL FUNCTION IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER
- Author
-
Tatsuki Koyama, Amy N. Luckenbaugh, Heather L. Huelster, Li-Ching Huang, Daniel A. Barocas, Zighuo Zhao, Daniel D. Joyce, Karen E. Hoffman, Ralph Conwill, and David F. Penson
- Subjects
Oncology ,Androgen deprivation therapy ,Prostate cancer ,medicine.medical_specialty ,business.industry ,Urology ,Internal medicine ,medicine ,medicine.disease ,Sexual function ,business ,Decreased sexual function - Abstract
INTRODUCTION AND OBJECTIVE:Decreased sexual function during androgen deprivation therapy (ADT) is well described; however, limited data exist regarding sexual function recovery following ADT use in...
- Published
- 2020
20. MP37-07 ASSOCIATION OF SARCOPENIA VERSUS OBESITY WITH SURVIVAL IN METASTATIC OR CASTRATE-RESISTANT PROSTATE CANCER
- Author
-
Heather L. Huelster, Mark C. Xu, Svetlana Avulova, Kelvin A. Moses, Zachary A. Glaser, and Jeremy B. Hatcher
- Subjects
Oncology ,Prostate cancer ,medicine.medical_specialty ,business.industry ,Urology ,Internal medicine ,Sarcopenia ,medicine ,Castrate-resistant prostate cancer ,medicine.disease ,business ,Obesity - Abstract
INTRODUCTION AND OBJECTIVE:The complex interplay between metabolic factors, body composition, and disease-specific outcomes in men with prostate cancer is poorly understood. Obesity (BMI ≥30kg/m2) ...
- Published
- 2020
21. Acute Renal Transplant Failure Secondary to an Obstructing Ileal Conduit Adenocarcinoma: Case Report and Literature Review
- Author
-
Melissa M. Straub Hogan, Heather L. Huelster, and Matthew J. Resnick
- Subjects
Adult ,Male ,medicine.medical_specialty ,Organoplatinum Compounds ,Urology ,MEDLINE ,Leucovorin ,Urinary Diversion ,Nephrectomy ,Text mining ,Fatal Outcome ,Antineoplastic Combined Chemotherapy Protocols ,Carcinoma ,medicine ,Humans ,Renal Insufficiency ,Neoplasm Staging ,business.industry ,Ureteral Neoplasms ,Disease progression ,medicine.disease ,Kidney Neoplasms ,Surgery ,Patient Care Management ,Ureter surgery ,Renal transplant ,Disease Progression ,Adenocarcinoma ,Neoplasm staging ,Fluorouracil ,Ureter ,business ,Tomography, X-Ray Computed ,Carcinoma, Signet Ring Cell - Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.